Suchergebnisse - "Ko, Bor-Sheng"

PubPharm (206)

31

Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia : A Taiwan observational study

enthalten in: Cancer reports (Hoboken, N.J.) | 2022

von Wang, Y. | Tien, F. | Tsai, C. | +6

32

Outcomes of Different Haploidentical Transplantation Strategies from the Taiwan Blood and Marrow Transplantation Registry

enthalten in: Cancers | 2022

von Tsai, X. | Chen, T. | Gau, J. | +6

33

Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma : a real-world experience

enthalten in: Annals of hematology | 2022

von Wang, Y. | Tsai, X. | Hou, H. | +15

CommentIn: Ann Hematol. 2022 Jul;101(7):1609-1610. - PMID 35218398

34

Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD : role of allogeneic stem cell transplantation in first remission

enthalten in: Bone marrow transplantation | 2022

von Tien, F. | Tsai, C. | Huang, S. | +20

35

The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan

enthalten in: PloS one | 2022

von Huang, H. | Chen, C. | Wang, C. | +4

36

Busulfan‐containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia : A Taiwan observational study

enthalten in: Cancer Reports | 2022

von Wang, Y. | Tien, F. | Tsai, C. | +6

37

Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience

enthalten in: Annals of hematology | 2021

von Wang, Y. | Tsai, X. | Hou, H. | +15

38

Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience

enthalten in: Annals of hematology | 2021

von Wang, Y. | Tsai, X. | Hou, H. | +15

39

Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience

enthalten in: Annals of hematology | 2021

von Wang, Y. | Tsai, X. | Hou, H. | +15

40

Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia : A Population-Based, Propensity Score-Matched Cohort Study

enthalten in: The oncologist | 2021

von Chen, M. | Huang, S. | Lin, C. | +4